Anesthesia Notes

Anesthesia

Inhalation Anesthetics


  • Commonly Used Agents
      - Isoflurane: Most frequently utilized inhalation anesthetic in the United States.
      - Sevoflurane: Common inhalation anesthetic widely used in general veterinary practice.

  • Rarely Used or Obsolete Agents
      - Desflurane: Rarely utilized within veterinary medicine.
      - Nitrous Oxide: No longer used frequently in veterinary practice; primarily used in dentistry.
      - Halothane, Enflurane, Methoxyflurane: No longer in active use.

  • Historical and Specialized Agents
      - Diethyl Ether: Historically used in the 1800s; still used in laboratory animal settings but is highly flammable and explosive.

  • Halogenated Anesthetics: Chemical and Physical Characteristics
      - General Properties
        - Most inhalant anesthetics are halogenated compounds; exceptions include nitrous oxide and diethyl ether.
        - Exist as liquids at room temperature.
        - Induction: Liquid anesthetic evaporates into the oxygen stream as it enters the vaporizer.
        - Delivery: Anesthetic gas is delivered via a breathing circuit and/or an endotracheal tube.
        - Chemical Structure Examples
        - Isoflurane: Involves elements such as fluorine (F), chlorine (Cl), oxygen (O), hydrogen (H), and carbon (C).
        - Sevoflurane: Includes CF₃ groups, oxygen (O), fluorine (F), and hydrogen (H).

  • Physical and Chemical Properties: Vapor Pressure and Vaporizers
      - Vapor Pressure Dynamics
        - Involves vaporization (liquid to gas) and condensation (gas to liquid).
        - Equilibrium defined by vaporization and condensation rates.
        - Vaporizer Requirements
        - Precision vaporizers must be agent-specific.
        - Isoflurane Precision Vaporizer: Use only with Isoflurane.
        - Sevoflurane Precision Vaporizer: Use only with Sevoflurane.
        - Non-precision vaporizers are not standard for modern agents.

  • Clinical Potency: Minimum Alveolar Concentration (MAC)
      - Definition of MAC: Lowest concentration in alveolar gas where 50% of patients exhibit no response to painful stimulus.
      - Variability and Potency Rules: Unique MAC values for each gas; lower MAC indicates higher potency.
      - Established MAC Values:
        - Isoflurane MAC: 1.3%
        - Sevoflurane MAC: 2.4%

  • Maintenance and Depth of Anesthesia
      - Relationship between MAC and Anesthetic Depth:
        - Light Anesthesia (Stage III, Plane 1): Achieved at 1 × MAC.
        - Moderate Anesthesia (Stage III, Plane 2): Achieved at 1.5 × MAC.
        - Deep Anesthesia (Stage III, Plane 3): Achieved at 2 × MAC.
        - Safety Protocol: Extended periods at high concentrations may cause anesthetic overdose and be fatal.

  • Anesthesia Case Studies and Calculations
      - Isoflurane Maintenance Calculation: 1.5 × 1.3% = 1.95%.
      - Sevoflurane Maintenance Calculation: 1.5 × 2.4% = 3.6%.
      - Hypothetical New Agent Scenario:
        - Maintained at 2% to 3%, MAC ranges from approximately 1.33% to 2.0%.
        - If MAC is 1.33%, it’s less potent than isoflurane but more potent than sevoflurane.

  • Solubility and the Partition Coefficient
      - Blood:Gas Partition Coefficient (λ): Indicates how quickly anesthetic moves from lungs to blood to brain.
      - Specific Values (λ blood:gas):
        - Desflurane: 0.45
        - Nitrous Oxide: 0.47
        - Sevoflurane: 0.65
        - Isoflurane: 1.4
        - Enflurane: 1.8
        - Halothane: 2.3
        - Methoxyflurane: 12
        - Alveolar Partial Pressure (PA) towards Inspired Partial Pressure (PI):
        - Fast-acting agents include N₂O, desflurane, and sevoflurane.
        - Intermediate agents: isoflurane, enflurane.
        - Slowest: halothane; slowest overall: methoxyflurane.

  • Clinical Considerations and Monitoring
      - Product Labeling and Packaging:
        - Isoflurane, USP: Available in bottles of 100 mL and 250 mL. Indicated for veterinary use in horses and dogs; nonflammable and nonexplosive.
        - SevoFlo (Sevoflurane): Available in 250 mL bottles; not for use in horses.
        - Patient Monitoring (Cardell Veterinary Monitor A2):
        - Heart Rate (HR): 107 BPM
        - Oxygen Saturation (SPO₂): 98%
        - Pulse Rate (PR): 115 BPM
        - End-Tidal CO₂ (EtCO₂): 53 mmHg
        - Respiratory Rate (RR): 18
        - Non-Invasive Blood Pressure (NIBP): 101/43 mmHg (Mean Arterial Pressure of 62).
        - Specific Equipment:
        - Nitrous Oxide Flow Meter: Measured in Liters Per Minute (LPM) at 760 MM pressure and 21°C; includes scales for O₂ and Nitrous Oxide, with a CC scale from 50 to 700 and a liter scale up to 15.


Injectable Anesthetics


  • Inhalant Agents:
      - Examples include Isoflurane, Sevoflurane, and Desflurane.
      - Utility: Primarily used for maintenance of general anesthesia, though they can be used for induction.
      - Recovery: Occurs due to rapid elimination through the patient's lungs. 

  • Injectable Agents:
      - Examples include Propofol, Etomidate, Alfaxalone, Ketamine, and Telazol.
      - Utility: Primarily used for induction of general anesthesia, though they can be used for maintenance. At lower doses, they may be used for sedation.
      - Recovery: Depends on the redistribution of the drug from the brain to other tissues, metabolism in the liver, and elimination through the kidneys. 

Classification of Injectable Anesthetics
  • Barbiturates: Traditional agents used as models for injectable behavior. 

  • Non-Barbiturates: Includes Propofol and Etomidate. 

  • Neuroactive Steroids: Includes Alfaxalone. 

  • Dissociatives: Includes Ketamine and Tiletamine. 

Pharmacological Principles of Injectable Agents
  • Pharmacokinetics Factors: Recovery and drug availability are influenced by three categories of factors:
      - Drug Factors: Lipid solubility, protein binding, and the specific mechanism of elimination.
      - Patient Factors: Body Condition Score (BCS), albumin levels, hepatic/renal insufficiency, hypothermia, and hypotension.
      - Anesthetist Factors: Administration of the "dose to effect." 

  • Bioavailability:
      - Any drug administered intravenously (IV) is 100% bioavailable (F=1).
      - Bioavailability is slightly lower via intramuscular (IM) administration and significantly less via subcutaneous (SC) administration. 

  • Distribution:
      - Vessel Rich Tissues (VRT): Includes the brain, heart, liver, and kidneys, which receive large amounts of drug immediately after injection due to high blood supply.
      - Lipid Solubility: All injectable anesthetic agents are highly lipid soluble, allowing them to cross the blood-brain barrier into the Central Nervous System (CNS). 

  • Metabolism and Excretion:
      - Metabolism occurs primarily as blood circulates through the liver, converting drugs into inactive substances.
      - Excretion occurs through the kidneys via the blood. Total body elimination takes hours to days. 

  • Redistribution:
      - This is the primary mechanism for recovery from the clinical effects of barbiturates and non-barbiturates.
      - As blood levels drop, the drug leaves the brain and redistributes to muscle and fat.
      - Thiopental IV Injection Model: Percentage of dose in tissues over time:
        - Blood: Drops rapidly almost immediately.
        - Vessel Rich Group: Peaks within minutes, then drops as drug redistributes.
        - Muscle Group: Rises and peaks around 16-32 minutes.
        - Fat: Rises slowly and stabilizes over 128 minutes. 

  • Partition Coefficient:
      - For injectables, this refers to the solubility in lipids versus water.
      - High Partition Coefficient: Indicates high lipid solubility; drugs enter the brain and take effect rapidly but also redistribute rapidly, resulting in a short duration of action. 

  • Ionization and pH:
      - Changes in pH can alter drug ionization and lipid solubility.
      - This is a potential problem for Barbiturates and Propofol, but rarely for others. 

  • Protein Binding:
      - Drug that is protein-bound remains in the serum and cannot move into tissue.
      - Barbiturates and Propofol: Significantly protein-bound.
      - Alfaxalone: Moderately protein-bound.
      - Dissociatives: Protein binding is insignificant.
      - Clinical Impact: Hypoproteinemia makes more "free" drug available to enter tissue, making a standard dose more profound. 

  • Factors Affecting Recovery Delay:
      - Low Body Fat: Recovery is delayed in animals with less fat for redistribution, such as patients with low BCS, pediatric patients, and sighthounds.
      - Organ Dysfunction: Hepatic or renal disease impedes metabolism and elimination.
      - Overdosing: Administering large or repeated boluses can overwhelm redistribution capacity, leading to prolonged anesthesia. Constant Rate Infusion (CRI) can be used safely to mitigate this with Propofol and Alfaxalone.


Barbiturates
  • Characteristics:
      - Categorized as ultra-short acting barbiturates.
      - All are controlled substances.
      - Examples include Thiopental, Thiamylal, and Methohexital.

  • Clinical Note:
      - Only ultra-short acting barbiturates serve as anesthetics.
      - Other barbiturates (non-anesthetics) are used for different purposes in veterinary medicine (e.g., Phenobarbital for seizures).

Propofol
  • General Properties:
      - A non-barbiturate, ultra-short acting injectable agent.
      - Not a controlled substance.
      - Must always be administered intravenously (IV).
      - Structure: Minimal water solubility; provided as a milky emulsion in oil with egg phospholipids.
      - Shelf Life: PropoFlo Plus has a 28-day shelf life.

  • Mechanism of Action:
      - Binds to GABA receptors (similar to barbiturates).

  • Administration Protocol (To Effect):
      1. Calculate low and high dose ranges.
      2. Administer frac{1}{2} of the low dose over 30,sec.
      3. Wait 30-60,sec.
      4. If needed, administer frac{1}{2} of the remaining low dose over 15,sec.
      5. Wait 30-60,sec.
      6. Administer the remainder of the low dose if needed.
      7. Continue in small boluses up to the high dose limit.

  • Action and Elimination:
      - Loss of consciousness occurs in less than 1,min.
      - Duration of action is only 5-10,min due to redistribution.
      - Complete recovery in 20-30,min due to rapid liver metabolism.

  • Maintenance Use:
      - Bolus: 0.5-2,mg/kg every 3-5,min to effect.
      - CRI: 0.05-0.1,mg/kg/min.
      - Note: Endotracheal intubation and oxygen supplementation are recommended even when not using inhalants.

  • Cautions:
      - Hypotensive, trauma, and shock patients.
      - Sighthounds and cats may experience prolonged recovery with repeated doses.

Etomidate
  • General Properties:
      - Non-barbiturate, ultra-short acting agent.
      - Not a controlled drug.
      - Expensive but has a wide safety margin and stable shelf life.

  • Mechanism:
      - Enhances GABA activity to induce hypnosis and unconsciousness.

  • Clinical Applications:
      - CNS: Not an analgesic; maintains cerebral perfusion, making it ideal for neuro-trauma.
      - CV/RESP: Minimal effect on cardiovascular and respiratory systems; maintains cardiac output and BP. Choice agent for heart disease/trauma.
      - Neonatal: Good for C-sections as it has minimal impact on neonates.

  • Side Effects and Considerations:
      - Painful IV injection.
      - Nausea and vomiting during induction/recovery.
      - Muscle twitching, tremors, or excitement.
      - Suppresses adrenal gland function (not for long-term maintenance).

  • Duration: Less than 5,min.

Alfaxalone
  • General Properties:
      - A neuroactive steroid and controlled drug.
      - Released in the US in 2018.
      - Acts similarly to propofol (GABA binding).

  • Administration:
      - Labeled for IV use (induction and maintenance).
      - Extended use (maintenance) is safe due to rapid hepatic metabolism and elimination (within a few hours).
      - Extra-label Use: Can be used via CRI or intramuscularly (IM) for deep sedation in fractious patients (e.g., follow with an IV catheter for induction).

  • Clinical Considerations:
      - Causes less respiratory depression than propofol (claim), but intubation readiness is mandatory.
      - Causes a transient drop in BP at induction.
      - Requires co-administration with sedatives (opioids, alpha-2 agonists, or acepromazine) for smooth recovery.

Dissociative Anesthetics: Ketamine
  • Mechanism:
      - Induces a cataleptoid state (trancelike) rather than general CNS depression. Inhibits NMDA (N-methyl-D-aspartate) receptors, preventing "wind-up" pain.

  • Control Class: Schedule III.

  • Clinical Signs:
      - Eyes remain open with central, dilated pupils (requires ophthalmic ointment every 1,hr).
      - Increased salivary and respiratory secretions.
      - Patient retains reflexes: pedal, palpebral, corneal, Photopupillary Light Reflex (PLR), pharyngeal, and laryngeal.
      - Muscle tone is retained; limbs may be rigid.

  • Pharmacokinetics:
      - Onset: 1-2,min (IV), 10,min (IM or PO in cats).
      - Duration: 20-30,min of surgical anesthesia.
      - Recovery: 2-6,hr, especially after IM.
      - Metabolism: Liver (dogs, horses) or excreted directly by kidneys (cats).

  • Analgesia: Provides good somatic analgesia but lacks visceral analgesia.

  • Contraindications:
      - Patients with seizure history, cranial trauma, or specific pre-existing heart conditions.

  • Ketamine-Diazepam Combination:
      - Equal volumes mixed in one syringe (draw Diazepam first).
      - Dosage: 5,mg/kg Ketamine and 0.25,mg/kg Diazepam.
      - Benefits: Improved muscle relaxation and smoother recovery.

Dissociative Anesthetics: Telazol
  • Composition:
      - A combination of Tiletamine (dissociative) and Zolazepam (benzodiazepine).

  • General Properties:
      - Sold as a powder; must be reconstituted.
      - Shelf Life: Reconstituted solution lasts 14,days chilled.
      - Control Class: Schedule III.

  • Administration:
      - IV, IM, or SC.

  • Clinical Considerations:
      - Dose-dependent CNS depression.
      - Onset: < 1,min (IV), 3-6,min (IM).
      - Duration: 20-30,min of surgical anesthesia.
      - Recovery: 2-4,hr following IM injection.
      - Increased secretions and retained reflexes (similar to Ketamine).
      - Metabolism: Liver metabolism and kidney excretion.
      - Contraindications: Patients with CNS signs, cardiac disease, hepatic disease


Anesthetic Adjuncts

Core Definitions of Anesthesia and Pharmacology

  • Anesthetic Agent: A substance that causes a loss of sensation, which may occur with or without a concomitant loss of consciousness.

  • Anesthetic Adjunct: A substance used in conjunction with an anesthetic agent to produce specific desired effects. These effects include, but are not limited to:     

    •  Sedation     

    •  Tranquilization     

    •  Muscle relaxation     

    •  Analgesia

  • Sedation: A state of Central Nervous System (CNS) depression and drowsiness. A key characteristic is that the patient can still be roused by noxious (painful) stimuli.

  • Tranquilization: A state where the patient is calm and quiet. The patient remains aware of their surroundings but is unconcerned by them.

  • Hypnosis: A sleeplike state from which the patient can be aroused if provided with sufficient stimulation.

  • Narcosis: A sleeplike state where the patient is not easily aroused. This state is specifically associated with the administration of narcotic agents.

  • Agonist: A drug that binds to and stimulates specific tissue receptors.

  • Antagonist: A drug that binds to a tissue receptor but does not stimulate a response; its primary function is to block the action of an agonist.

  • Partial Agonist: A drug that binds to a tissue receptor and elicits only a partial or incomplete response.

  • Agonist–Antagonist: A drug that binds to two or more types of receptors, acting as an agonist (stimulating) for one type while acting as an antagonist (blocking) for another.

Alpha 2 Agonists: Overview and Specific Agents

  • Primary Effects: These agents produce sedation, provide analgesia, and induce muscle relaxation.

  • Usage Con: They can be used alone for minor procedures or in combination with other anesthetic agents and adjuncts.

  • Control Status: These are not classified as controlled substances.

  • Administration Routes: Typically administered via Intramuscular (IM) or Intravenous (IV) injection. An oral formulation of Dormosedan (Detomidine) also exists.

  • Reversibility: A defining feature of this class is that their effects are completely reversible.

  • Specific Small Animal Agents:     

    •  Dexmedetomidine: Brand name Dexdomitor.

  • Specific Equine and Large Animal Agents:     

    •  Detomidine: Brand name Dormosedan. Available as an injectable or a gel for horses; the gel formulation is also used for canines.     

    •  Xylazine: Brand name Rompun. Used in food animals and horses.     

    •  Romifidine: Brand name Sedivet. Used in horses.

Alpha 2 Agonists: Mechanism and Pharmacokinetics

  • Mechanism of Action: These drugs bind to alpha 2 receptors of the sympathetic nervous system.     

    •  Alpha 1 Receptors: Involved in vasoconstriction in the skin and GI tract.     

    •  Alpha 2 Receptors: Inhibit the release of norepinephrine, providing negative feedback.     

    •  Beta 1 and 2 Receptors: Responsible for the "fight or flight response," including increased heart rate (HR), increased contractility, vasodilation, and bronchodilation.

  • Duration of Action (IM Administration):     

    •  Onset: 15-30\,minutes     

    •  Duration: 1-2\,hours     

    •  Complete Recovery: 2-4\,hours

  • Duration of Action (IV Administration):     

    •  Onset: 5-15\,minutes     

    •  Duration: Up to 1\,hour     

    •  Complete Recovery: 2-4\,hours

  • Elimination and Metabolism:     

    •  Metabolized by the liver.     

    •  Excreted by the kidneys.     

    •  Reversal via an alpha 2 antagonist occurs within 5-10\,minutes post-administration, though the body still must metabolize the original agonist to fully eliminate it.

Alpha 2 Agonists: Clinical Considerations and Concentrations

  • Standard Uses:     

    •  Used alone for non-invasive procedures (e.g., radiographs, bandage changes).    

    •  Used in combination for short surgical procedures or standing sedation.

  • Clinical Side Effects:     

    •  Dose-dependent sedation.     

    •  Dose-dependent Cardiovascular (CV) depression, characterized by Bradycardia and Hypotension.     

    •  Dose-dependent respiratory depression.     

    •  Vomiting (very common in dogs and cats).    

    •   Muscle relaxation and short-lived analgesia.

  • Administration Safety:     

    •  Dosing should be based on body surface area rather than just weight; manufacturers provide specific charts.     

    •  Patients should be kept quiet post-injection to allow the drug to take effect. Sudden stimuli may cause an animal to rouse abruptly.

Reversal Agents for Alpha 2 Agonists

  • Agent Pairings:     

    •  Dexmedetomidine: Reversed with Atipamezole (Antisedan).     

    •  Detomidine: Reversed with Tolazoline or Yohimbine.     

    •  Xylazine: Reversed with Tolazoline or Yohimbine.

  • Administration Rules:     

    •  Small animals: Reversal agents should be given IM even if the sedative was given IV.     

    •  Large animals: Reversal agents are typically given IV.     

    •  Dose adjustment: If the patient has been sedated for more than 30\,minutes, a lower dose of the reversal agent may be used.     

    •  Limitation: Reversal agents only work on alpha 2 agonists and do not affect other adjuncts or anesthetic agents.

Dormosedan Gel (Detomidine Hydrochloride)

  • Route: Only alpha 2 agonist labeled for Oral Transmucosal (OTM) administration.

  • Target Species: Labeled for horses (sub-lingual administration) and dogs (cheek pouch administration).

  • Absorption: Absorbed through the mucous membranes; it must not be swallowed.

  • Timing: Takes approximately 45\,minutes to take effect with a duration of 30\,minutes.

  • Clinical Use: Used for mild sedation in anxious or aggressive patients. In dogs, it can be combined with Acepromazine or Butorphanol for deeper sedation.

  • Note: This formulation provides NO analgesic effects.

Acepromazine (Phenothiazine Tranquilizer)

  • Primary Functions: Calms the patient, relieves anxiety, and ensures a smooth induction into anesthesia.

  • Administration Routes: Subcutaneous (SC), IM, IV, and oral (po).

  • Pharmacological Effects:     

    •  Vasodilation and Hypotension, which is more pronounced at higher doses.     

    •  Reduced cardiac output.     

    •  Minimal respiratory depression.     

    •  Antiemetic and Antihistamine effects.     

    •  Analgesia: Not analgesic on its own, but it potentiates (increases the effectiveness of) other analgesic agents.

  • Clinical Concerns:     

    •  Prolonged sedation is common in pediatric, geriatric, or debilitated patients.     

    •  Breed Sensitivities: Herding breeds, Boxers, and Giant breeds are known to be sensitive to the drug.     

    •  Seizures:Historic concern that it lowers the seizure threshold; while modern evidence is ambiguous, most veterinarians avoid it in patients with a history of seizures.

  • Equine-Specific Issues:     

    •  May cause excitement.     

    •  Must be given Intravenously; never into an artery.     

    •  Can cause permanent penile prolapse; consult owners before use in breeding stallions.

Benzodiazepines: Diazepam, Midazolam, and Zolazepam

  • Classification: Described as "hypnotic sedatives" and anxiolytics. Diazepam and Midazolam are also primary anticonvulsants.

  • Legal Status: Controlled substances.

  • Routes: Administered IM or IV.

  • Mechanism and Elimination:     

    •  Depress the CNS by increasing the activity of GABA, an inhibitory neurotransmitter.     

    •  Onset: Rapid with IV injection; 15\,minutes with IM injection.     

    •  Duration: 1-4\,hours or more.     

    •  Metabolism/Excretion: Liver and kidneys.     

    •  Reversal: Can be reversed with Flumazenil, though this is rare in clinical practice.

  • Clinical Considerations:     

    •  Provides mild tranquilization and sedation with minimal CV depression.     

    •  No analgesic effect.     

    •  Causes respiratory depression in neonates; avoid in C-section patients.     

    •  May cause paradoxical dysphoria or excitement in young animals if given alone.     

    •  May cause ataxia in large animals if given alone.

  • Specific Drug Notes:     

    •  Diazepam: Not water-soluble. Do not mix in a syringe with anything except Ketamine. Flush catheters with saline between drugs. Poor IM absorption in dogs. Rapid IV administration must be avoided (30-45\,second delivery required) to prevent bradycardia, hypotension, or apnea. Also functions as an appetite stimulant.     

    •  Midazolam: Water-soluble and can be mixed with other drugs. Well absorbed and not painful when given IM.     

    •  Zolazepam: Found only in the combination product Telazol (combined with Tiletamine). In dogs, it is metabolized rapidly; if the Tiletamine is still active, a rough recovery may occur. Diazepam or Midazolam can be used to smooth this recovery.

Anticholinergics: Glycopyrrolate and Atropine

  • Primary Use: Commonly used as a premedication to prevent bradycardia and reduce secretions. Atropine is also vital for cardiac emergencies.

  • Routes: IV, IM, SC.

  • Mechanism of Action:     

    •  Classified as Parasympatholytics (antagonists of acetylcholine).     

    •  Prevents bradycardia resulting from vagal stimulation.     

    •  Reduces secretions from the salivary glands, respiratory tract, and tear ducts.

  • Onset and Duration:     

    •  IM/SC: Onset in 30\,minutes, duration of 2\,hours.     

    •  IV (Atropine): Onset in 1\,minute, short duration.

  • Clinical Considerations:     

    •  Administer 20-30\,minutes prior to induction.     

    •  Respiratory: Secretions can become thick, potentially causing airway blockages. Bronchodilation may increase anatomic dead space.     

    •  Cardiovascular: Should be avoided in patients with pre-existing tachycardia.    

    •  Large Animals: Not used routinely because they inhibit intestinal peristalsis; can cause colic in horses and bloat in ruminants.


Local Anesthetics

Comparison of Local and General Anesthesia

  • Site of Action: Local anesthesia acts specifically on the Peripheral Nervous System (PNS) or the spinal cord. It does not act on the brain.

  • Level of Consciousness: Local anesthesia causes a loss of sensation in a targeted area but does not result in a loss of consciousness.

  • Scope of Effect: The effect is exerted in a specific localized area rather than systemically across the whole body.

Clinical Applications of Local Anesthesia by Species

  • Ruminants:     

    •  Used as a primary agent or alongside other drugs for standing procedures.     

    •  Common applications include obstetric procedures, abdominal surgeries, and dehorning.

  • Equine:     

    •  Often combined with sedatives or tranquilizers.     

    •  Common applications include wound repair and various procedures on the limbs.     

    •  Used diagnostically via nerve blocks to identify the source of lameness in horses.

  • Canine and Feline:     

    •  Typically used as an adjunct to general anesthesia to enhance analgesia.     

    •  Common applications include declaws (onychectomy), tooth extractions, and orthopedic surgeries.

Pharmacological Profiles of Local Anesthetic Agents

  • Lidocaine:     

    •  Onset of Action: Rapid onset.     

    •  Duration: Lasts for 1-2\,\{hours}.     

    •  Available Concentration: Typically a 2\,\{\%} solution.    

    •   Administration Note: Can be diluted with saline to a 0.5\,\{\%} concentration for use.

  • Bupivacaine:     

    •  Onset of Action: Takes approximately 20\,\{min} to take effect.     

    •  Duration: Lasts up to 6\,\{hours}.     

    •  Available Concentration: Typically a 0.5\,\{\%} solution.     

    •  Administration Note: Can be diluted with saline to a 0.25\,\{\%} concentration.

  • Mepivacaine:    

    •  Onset of Action: Rapid onset.     

    •  Duration: Lasts for 2-3\,\{hrs}.     

    •  Tissue Response: Causes less tissue irritation compared to lidocaine; frequently used in horses.

Mechanism of Action and Physiological Effects

  • Cellular Mechanism: Local anesthetics block sodium (Na) gates within neurons. This action prevents the depolarization of the cell membrane, which stops the transmission of impulses down the neuron.

  • Sensory Nerves: Blockade prevents impulses that transmit the sensation of pain from the Peripheral Nervous System (PNS) to the Central Nervous System (CNS).

  • Motor Nerves: Blockade prevents impulses from the CNS from reaching the muscles, causing immobilization or weakness.

  • Autonomic Nerves:     

    •  Sympathetic Blockade: Blocks impulses from the sympathetic ganglia (located near the spinal cord) to the blood vessels, resulting in the blockage of vasoconstriction.     

    •  Parasympathetic Nerves:These are generally not affected by local anesthetics as their ganglia are located in the brain stem.

Metabolism and Elimination

  • Reversal: The anesthetic effect reverses as the drug diffuses away from local tissues and enters the circulatory system.

  • Metabolism: The circulating drug is broken down by hepatic (liver) metabolism.

  • Excretion: The resulting metabolites are excreted through the kidneys.

Clinical Considerations and Safety Standards

  • Sedation: Local anesthetics provide analgesia but no sedation; patients remain conscious and capable of sudden movement.

  • Systemic Safety:     

    •  Minimal impact on the cardiovascular or respiratory systems if dosed correctly.    

    •  Systemic Toxicity: Occurs if the maximum dose is exceeded.     

    •  Maximum Dosage Limits:        

      •   Lidocaine (Cats and Goats): 2\,\{mg/kg}.         

      •  Lidocaine (Other Species): 8\,\{mg/kg}.         

      •  Bupivacaine (All Species): 2\,\{mg/kg}.

  • Administration Technique:     

    •  The drug must be injected near the nerve, not directly into the nerve.     

    •  Contraindication: Do not administer intravenously; always aspirate before injecting to ensure a vessel has not been hit.     

    •  Wait Time: Time must be allowed for the drug to spread through the tissue to achieve the full effect.     

    •  Epinephrine Use: Mixed with lidocaine to cause local vasoconstriction, which prolongs the presence of the drug in the tissue. However, it should never be used on ears, tails, or digits, and should not be used along incision sites.

  • Benefits and Risks:     

    •  Can significantly reduce the required dose of general anesthetic agents.     

    •  Provides prolonged post-operative analgesia.     

    •  May cause temporary paresis (weakness) or paralysis; in large animals, this can lead to ataxia or injury.     

    •  Patients may self-traumatize "numb" tissue during the recovery phase.

Techniques for Administration

  • Topical: Applied directly to surfaces. Minimal effect on intact skin but effective on mucous membranes (larynx for intubation, urethra for catheterization, and cornea for tonometry using proparacaine or tetracaine).

  • Infiltration: Injection into subcutaneous tissue near a nerve.     

    •  Preparation: Clean and disinfect the site; clip and scrub as for surgery.     

    •  Equipment: Small gauge needles (25\,\{g} for small animals; up to 20\,\{g} for large animals).     

    •  Comfort: Subsequent injections should be placed through skin already desensitized by previous injections. Sodium bicarbonate may be added to lidocaine in a \frac{1}{9} ratio to reduce the stinging sensation/tissue irritation.

  • Splash Blocks: Application of lidocaine or bupivacaine directly to an open wound. Risk of overdose due to systemic uptake.

Specific Nerve and Infiltration Blocks

  • Equine Diagnostic Nerve Blocks: Used to locate lameness by starting with distal nerves and moving proximally. Blocks include:     

    •  Palmar / Plantar Block.     

    •  Abaxial sesamoid block.     

    •  Distal metacarpal block (Low 4 Point Block).     

    •  Proximal metacarpal block (High 4 Point Block).

  • Cornual Nerve Block: Used for dehorning cattle. Requires injection of 5-10\,\{ml} of lidocaine subcutaneously along the nerve.

  • Ring Blocks (Ruminants/Small Animals):     

    •  Cattle: Used for the base of the horn, teat lacerations, or foot lesions. Do not use lidocaine with epinephrine.     

    •  Cats (Onychectomy): A ring of lidocaine/bupivacaine is injected proximal to the carpus.     

  • Intratesticular Block (IT Block): Used for castrations. Involves injecting 1\,\{mg/kg} lidocaine plus 1\,\{mg/kg} bupivacaine, with half the total volume administered into each testicle. Use a 25\,\{g} or 22\,\{g} needle (1.5\,\{inch} for large dogs), aspirate, and inject as the needle is withdrawn.

  • Line Block: Lidocaine is infused subcutaneously as the needle is withdrawn along an incision line. May fail to anesthetize deep tissues/muscle and may cause healing-interfering edema.

  • Inverted L or 7 Block: Used in ruminants to block superficial nerves of the paralumbar fossa.      Procedure:Locate the transverse process of L_2 (caudal to the last rib). Use an 18-20\,\{g}, 3\,\{inch} needle. Inject 5\,\{ml} per site while withdrawing, moving caudally along L_2-L_4. Return to the first site and inject ventrally, parallel to the last rib, ensuring deep muscle tissue is also infused.

Intraarticular Anesthesia

  • Requirements: Strict asepsis is mandatory. Site must be clipped and receive a surgical scrub for 10\,\{minutes} (typically povidone iodine and alcohol). A sterile workspace and a brand-new bottle of anesthetic are required.

  • Common Joints:     

    •  Coffin joint.     

    •  Fetlock.     

    •  Carpus (Radiocarpal and Carpometacarpal).     

    •  Tarsus (Tibiotarsal, Distal Intertarsal [DIT], and Tarsometatarsal [TMT]).

  • Note: Intraarticular blocks affect only the joint, not structures distal to it.

Regional Anesthesia Techniques

  • Paravertebral Block: Blocks dorsal and ventral nerve roots emerging from intervertebral foramina. Provides anesthesia and motor blockade to the muscle wall, peritoneum, and skin. Requires a 7.5\,\{cm} needle.

  • Intravenous Regional Anesthesia (Bier Block):     

    •  Drug Restriction: Use only lidocaine.     

    •  Method: A tourniquet or blood pressure cuff is applied to a limb distal to which anesthesia is required (e.g., for mass removal or digit amputation). An IV catheter is placed in the radial or lateral saphenous vein.     

    •  Procedure: An Esmarch bandage may be used to exsanguinate the limb before the tourniquet is tightened. Inject 10-15\,\{ml} of lidocaine for an adult cow.    

    •  Onset/Duration: Onset takes 15\,\{minutes}; duration is approximately 90\,\{minutes}.

Epidural Anesthesia and Analgesia

  • Mechanism: Anesthesia is injected into the space between the dura mater and the vertebrae, acting on spinal nerves (sensory, motor, and autonomic).

  • Agents: Lidocaine or bupivacaine for anesthesia; opioids for analgesia.

  • Complications: Infection, motor paralysis of hind limbs, and sympathetic blockade (causing vasodilation and hypotension).

  • Hanging Drop Technique: Used to confirm needle placement. A drop of saline/anesthetic is placed in the needle hub; it is "sucked in" when the needle enters the negative pressure of the epidural space after popping through the ligamentum flavum.

  • Species Specifics:     

    •  Cattle: Injection site at Cy_1-Cy_2. Used for tail, perineum, vulva, and rectum procedures. Doses of 5-10\,\{ml} of 2\,\{\%} lidocaine are standard; higher doses (up to 150\,\{ml}) cause cranial spread and recumbency.     

    •  Equine: Only caudal epidurals (Cy_1-Cy_2) are performed to avoid dangerous hind leg paralysis. Dose is typically 5\,\{ml} of lidocaine or mepivacaine.     

    •  Small Animal: Site is the lumbosacral space. Used with general anesthesia. Requires a spinal needle (1.5-3.5\,\{inches}, 20\,\{g}). Must aspirate to ensure the needle is not in the subarachnoid space (indicated by Cerebrospinal Fluid [CSF]).    

    •  Sheep & Goats: Lumbosacral injection similar to dogs; carries a risk of entering the subarachnoid space and often produces recumbency.